key: cord-0733820-xrjh2zan authors: Benucci, Maurizio; Giannasi, Gianfranco; Cecchini, Paolo; Gobbi, Francesca Li; Damiani, Arianna; Grossi, Valentina; Infantino, Maria; Manfredi, Mariangela title: COVID‐19 pneumonia treated with Sarilumab: A clinical series of eight patients date: 2020-06-16 journal: J Med Virol DOI: 10.1002/jmv.26062 sha: 68d0941328067c626c7e519ab72dfc7b605252f9 doc_id: 733820 cord_uid: xrjh2zan The development of cytokine release syndrome and T cell abnormalities plays a key role in the progression of Coronavirus disease in 2019 (COVID-19). Under these circumstances, persistent viral stimulation leads to a significant increase in circulating cytokines such as interleukin (IL) -6, IL-10 and TNF-α. We describe a clinical series of eight patients treated with Sarilumab an IL-6R inhibitor administered early in Covid-19 pneumonia. This article is protected by copyright. All rights reserved. To the Editor, We read with interest the work by Luo et al, 1 Table 1 shows the variation of the parameters, both laboratory and functional, in our clinical series of the eight treated patients. Seven of them showed an improvement of the Horovitz index and a progressive reduction in the echo score (Figures 1 and 2 ). In these patients, aggressive and early treatment with an IL-6 inhibitor led to discharge within 14 days of hospitalization and seven out of eight patients resulted negative at the molecular test. An 83-year-old patient had no improvement in Horovitz's functional index or echo score and died 13 days after hospitalization. There is also a progressive reduction in the SAA and CRP inflammation parameters. In RA, the determination of early synovitis may predict erosive damage over time 6 and the treat-to-target strategy is capable of determining clinical remission and blockage of radiological damage. 7 In this context, timing is even more fundamental. Hence, the rheumatologic concept of a window of opportunity in treating RA can be translated into therapeutic strategies for dealing with the COVID-19 pandemic. T0 lymphocyte cells/mcL T1 T2 T0 SAA mg/L T1 T2 T0 IL-6 pg/mL T1 T2 T0 CRP mg/dL T1 T2 560 590 630 961 54 15, 6 86 >200 >200 22 6, 5 2, 3 480 459 638 846 708 17, 3 68 >200 >200 36, 1 9, Tocilizumab treatment in COVID-19: a single center experience Clinical features of patients infected with 2019 novel coronavirus in Wuhan Off-label use of Tocilizumab in patients with SARS-CoV-2 Infection Effective Treatment of Severe COVID-19 Patients with Tocilizumab Proposal for international standardization of the use of lung ultrasound for patients with COVID-19: a simple, quantitative, reproducible method Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update